

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Clover Biopharmaceuticals, Ltd.

三葉草生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2197)

**VOLUNTARY ANNOUNCEMENT
CLOVER'S COVID-19 VACCINE CANDIDATE DEMONSTRATES
STRONG CROSS-NEUTRALIZATION AGAINST OMICRON
AS A HOMOLOGOUS BOOSTER**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Clover Biopharmaceuticals, Ltd. (the “**Company**” or “**Clover**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest clinical development status of the core product of the Group.

The Company is pleased to announce that new positive clinical data in individuals vaccinated with a third dose of SCB-2019 (CpG 1018/Alum) as a homologous booster against the Omicron variant. A homologous booster dose of SCB-2019 (CpG 1018/Alum) demonstrated a significant, 19-fold increase in neutralizing antibody levels against the Omicron BA.2 variant compared to pre-booster levels among baseline seronegative participants.

In this study, a homologous booster dose of SCB-2019 (CpG 1018/Alum) in individuals who previously received two doses of SCB-2019 induced a robust and rapid neutralizing antibody immune response in this preliminary analysis. A cohort comprised of individuals who were baseline seronegative (individuals with no evidence of natural infection using anti-N antibody testing and observed waning neutralizing antibody levels after the second dose and prior to the booster dose) demonstrated a robust 19-fold increase against the Omicron BA.2 variant and a 12-fold increase in neutralizing antibodies against the Omicron BA.1 variant compared to pre-booster levels.

This double-blind, randomized, controlled study evaluated the immunogenicity and safety of SCB-2019 (CpG 1018/Alum) as a homologous booster dose administered approximately six months following a two-dose primary vaccination with SCB-2019 (CpG 1018/Alum). In total, 3,755 participants were recruited in Brazil, the Philippines and Columbia. The Company will further evaluate study participants for immunogenicity, durability, and safety, and intends to make data available in a manuscript for peer-review publication when available.

The Company remains focused on completing regulatory submissions to the National Medical Products Administration (國家藥品監督管理局) of China, the European Medicines Agency, and the World Health Organization for SCB-2019 (CpG 1018/Alum) in the second half of 2022, while concurrently preparing for global commercialization.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to ultimately commercialize SCB-2019 (CpG 1018/Alum) successfully.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Clover Biopharmaceuticals, Ltd.
Dr. Peng LIANG
Chairman of the Board

Shanghai, PRC, June 27, 2022

As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG, Mr. Dong LYU, Dr. Donna Marie AMBROSINO and Dr. Ralf Leo CLEMENS as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.